<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>
<channel>
	<title>Aesthetics Product Guide &#187; Cardium Therapeutic</title>
	<atom:link href="http://blog.aestheticsproductguide.com/tag/cardium-therapeutic/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.aestheticsproductguide.com</link>
	<description>A comprehensive guide to aesthetics products for medical professionals</description>
	<lastBuildDate>Mon, 27 Sep 2010 15:54:09 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.3</generator>
		<item>
		<title>Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) and ExcellagenFX(TM)</title>
		<link>http://blog.aestheticsproductguide.com/2009/12/28/cardium-files-fda-510k-application-for-u-s-marketing-clearance-of-excellagenxltm-and-excellagenfxtm/</link>
		<comments>http://blog.aestheticsproductguide.com/2009/12/28/cardium-files-fda-510k-application-for-u-s-marketing-clearance-of-excellagenxltm-and-excellagenfxtm/#comments</comments>
		<pubDate>Mon, 28 Dec 2009 07:02:35 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Cardium Therapeutic]]></category>
		<category><![CDATA[Excellagen(TM)]]></category>
		<category><![CDATA[ExcellagenFX(TM)]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Tissue Repair Company]]></category>
		<guid isPermaLink="false">http://www.aestheticsproductguide.com/blog/?p=215</guid>
		<description><![CDATA[Cardium Therapeutic has announced that its wholly-owned subsidiary, Tissue Repair Company, submitted a 510(k) premarket notification filing with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its Excellagen(TM) product candidate based on positive data from the Company&#8217;s recently completed Phase 2b Matrix clinical study. ExcellagenXL(TM) and ExcellagenFX(TM) are advanced wound care management [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blog.aestheticsproductguide.com/files/2009/12/Cardium-Therapeutic.png"><img class="alignleft size-full wp-image-216" style="margin: 5px" src="http://blog.aestheticsproductguide.com/files/2009/12/Cardium-Therapeutic.png" border="0" alt="Cardium Therapeutic" width="200" height="71" /></a>Cardium Therapeutic has announced that its wholly-owned subsidiary, Tissue Repair Company, submitted a 510(k) premarket notification filing with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its Excellagen(TM) product candidate based on positive data from the Company&#8217;s recently completed Phase 2b Matrix clinical study. ExcellagenXL(TM) and ExcellagenFX(TM) are advanced wound care management medical devices comprising customized collagen protein-based topical gels designed for use by health care professionals for patients with dermal wounds.</p>
<p>The the full story, <a href="http://www.prnewswire.com/news-releases/cardium-files-fda-510k-application-for-us-marketing-clearance-of-excellagenxltm-topical-gel-and-excellagenfxtm-flowable-collagen-protein-based-matrix-for-diabetic-pressure-and-venous-ulcers-and-other-dermal-wounds-78417502.html" target="_blank">Click Here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.aestheticsproductguide.com/2009/12/28/cardium-files-fda-510k-application-for-u-s-marketing-clearance-of-excellagenxltm-and-excellagenfxtm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

